Data Sheet (Cat.No.T11548L)

TargetMol

HCV-IN-7 hydrochloride

Chemical Properties



CAS No. : 1449756-87-9

Formula: C40H50Cl2N8O6S

Molecular Weight: 841.85

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor [IC50s: 3-47 pM], exhibiting a superior pan-genotypic profile, a good pharmacokinetic profile, and favorable liver uptake.
Targets(IC50)	Others,HCV Protease
In vitro	HCV-IN-7 hydrochloride (10 μM) has cytotoxicity of 14%, 22%, 36% in Huh7, HepG2 and HEK cells, respectively. ?HCV-IN-7 hydrochloride has a less complex central tricyclic core as novel and potent pan-genotypic NS5A inhibitors with good pharmacokinetic profile. HCV-IN-7 hydrochloride inhibits GT1b (IC50=12 pM), GT2a (IC50=5 pM), GT1a (IC50=27 pM), GT3a (IC50=47 pM), GT4a (IC50=3 pM), GT6a (IC50=28 pM). ?HCV-IN-7 hydrochloride (10 μM) has 12%, 42%, 12% inhibition for CYP2D6, CYP2C9, CYP3A4, respectively.
In vivo	HCV-IN-7 hydrochloride (po; 10 mg/kg) has a Cmax of 1 μM and an AUClast of 6 μM for rats. ?HCV-IN-7 hydrochloride (iv; 1 mg/kg) has a T1/2 of 4 hours, CL of 6 mL/min/kg, and a Vss of 2 L/kg for dog. ?HCV-IN-7 hydrochloride (po; 10 mg/kg) has a Cmax of 5 μM and an AUClast of 49 μM for dog.?HCV-IN-7 hydrochloride (iv; 1 mg/kg) has a T1/2 of 2 hours, CL of 11 mL/min/kg, and a Vss of 2 L/kg for rats.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1879 mL	5.9393 mL	11.8786 mL
5 mM	0.2376 mL	1.1879 mL	2.3757 mL
10 mM	0.1188 mL	0.5939 mL	1.1879 mL
50 mM	0.0238 mL	0.1188 mL	0.2376 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ramdas V, et al. Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. J Med Chem. 2019 Dec 12;62(23):10563-10582.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481